Zinc and its relation to prostate tumours

Czech version

Authors: J. Gumulec ¹; M. Masařík ¹; R. Hrabec ²; A. Rovný ²; H. Binková ³; P. Babula ⁴; V. Adam ⁵; R. Kizek ⁵
Authors‘ workplace: Ústav patologické fyziologie, Lékařská fakulta Masarykova univerzita Přednostka: prof. MUDr. Anna Vašků, CSc. ¹; Oddělení urologie, Fakultní nemocnice u sv. Anny, Brno Primář: MUDr. Arne Rovný ²; Klinika otorinolaryngologie a chirurgie hlavy a krku Lékařská fakulta, Masarykova univerzita Přednosta: prof. MUDr. Rom Kostřica, CSc. ³; Ústav přírodních léčiv, Veterinární a farmaceutická fakulta v Brně Děkan: doc. RNDr. Milan Žemlička, CSc. ⁴; Ústav chemie a biochemie, Mendelova univerzita v Brně Děkan: prof. Ing. Ladislav Zeman, CSc. ⁵
Published in: Prakt. Lék. 2010; 90(8): 455-459
Category: Reviews

Overview

Zinc ions (Zn²⁺) are essential elements necessary for the normal function of mammalian cells. They participate in the regulation of the immune system, gene expression, energy metabolism, signal transduction and perform a structural function. However, an increased level of these ions is toxic, and so needs to be controlled. This control is primarily carried out by zinc transporters and zinc-binding proteins, in particular, metallothioneins. Prostatic tissue is very specific in Zn²⁺metabolism. Its cells accumulate a greater quantity of these ions (up to ten times more). Prostate cancer, a common cancer of men, is characterized by diverse and not very clear mechanisms, which serve to maintain Zn²⁺ levels. This unusual metabolism of Zn²⁺ has two important implications:

participation in the pathogenesis of the disease (due to apoptosis) and

increased serum levels of metallothioneins (with potential use of these proteins as markers for this disease).

Keywords:
zinc, metallothionein, thiols, resistance, tumour disease.

Sources

1. Giles, G. The epidemiology of prostate cancer. In: W.D. Foulkes and K.A. Cooney (Eds.). Male reproductive cancers epidemiology, pathology and genetics. New York, Dordrecht, Heidelberg, London: Springer Verlag, 2009.

2. ÚZIS. Novotvary 2007 ČR. Praha: Ústav zdravotnických informací a statistiky ČR ve spolupráci s Národním onkologickým registrem ČR, 2010.

3. Begin, L.R., Bismar, T.A. Prostate cancer: pathological perspective. In: W.D. Foulkes and K.A. Cooney (Eds.). Male reproductive cancers epidemiology, pathology and genetics. New York, Dordrecht, Heidelberg, London: Springer Verlag, 2009.

4. Medrano, A., Fernandez-Novell, J.M., Ramio, L. et al. Utilization of citrate and lactate through a lactate dehydrogenase and ATP-regulated pathway in boar spermatozoa. Mol. Reprod. Dev. 2006, 73, p. 369-378.

5. Franklin, R.B., Feng, P., Milon, B. et al. hZIP1 zinc uptake transporter down regulation and zinc depletion in prostate cancer. Mol. Cancer 2005, 4, p. 13.

6. Costello, L.C., Franklin, R.B. The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots. Mol. Cancer 2006, 5, p. 13.

7. Franklin, R.B., Costello, L.C. The important role of the apoptotic effects of zinc in the development of cancers. J. Cell. Biochem. 2009, 106, p. 750-757.

8. Kambe, T., Yamaguchi-Iwai, Y., Sasaki, R. et al. Overview of mammalian zinc transporters. Cell. Mol. Life Sci. 2004, 61, p. 49-68.

9. Hogstrand, C., Kille, P., Nicholson, R.I. et al. Zinc transporters and cancer: a potential role for ZIP7 as a hub for tyrosine kinase activation. Trends Mol. Med. 2009, 15, p. 101-111.

10. Costello, L.C., Franklin, R.B. The intermediary metabolism of the prostate: A key to understanding the pathogenesis and progression of prostate malignancy. Oncology 2000, 59, p. 269-282.

11. Song, Y., Elias, V., Loban, A. et al. Marginal zinc deficiency increases oxidative DNA damage in the prostate after chronic exercise. Free Radic. Biol. Med. 2010, 48, p. 82-88.

12. Hambidge, M. Human zinc deficiency. J. Nutr. 2000, 130, p. 1344S-1349S.

13. Oteiza, P.I., Mackenzie, G.G. Zinc, oxidant-triggered cell signaling and human health. Mol. Asp. Med. 2005, 26, p. 245-255.

14. Laity, J.H., Andrews, G.K. Understanding the mechanisms of zinc-sensing by metal-response element binding transcription factor-1 (MTF-1). Arch. Biochem. Biophys. 2007, 463, p. 201-210.

15. Coyle, P., Philcox, J.C., Carey, L.C. et al. Metallothionein: The multipurpose protein. Cell. Mol. Life Sci. 2002, 59, p. 627-647.

16. Vallee, B.L., Falchuk, K.H. The biochemical basis of zinc physiology. Physiol. Rev. 1993, 73, p. 79-118.

17. Eide, D.J. Zinc transporters and the cellular trafficking of zinc. Biochim. Biophys. Acta-Mol. Cell Res. 2006, 1763, p. 711-722.

18. Gaither, L.A., Eide, D.J. Eukaryotic zinc transporters and their regulation. Biometals, 2001, 14, p. 251-270.

19. Costello, L.C., Liu, Y.Y., Zou, J. et al. Evidence for a zinc uptake transporter in human prostate cancer cells which is regulated by prolactin and testosterone. J. Biol. Chem. 1999, 274, p. 17499-17504.

20. Gitan, R.S., Eide, D.J. Zinc-regulated ubiquitin conjugation signals endocytosis of the yeast ZRT1 zinc transporter. Biochem. J. 2000, 346, p. 329-336.

21. Urani, C., Melchioretto, P., Gribaldo, L. Regulation of metallothioneins and ZnT-1 transporter expression in human hepatoma cells HepG2 exposed to zinc and cadmium. Toxicol. Vitro. 2010, 24, p. 370-374.

22. Kobayashi, T., Beuchat, M.H., Lindsay, M. et al. Late endosomal membranes rich in lysobisphosphatidic acid regulate cholesterol transport. Nat. Cell Biol. 1999, 1, p. 113-118.

23. Sorensen, M.B., Stoltenberg, M., Juhl, S. et al. Ultrastructural localization of zinc ions in the rat prostate: An autometallographic study. Prostate 1997, 31, p. 125-130.

24. Margoshes, M., Vallee, B.L. A cadmium protein from equine kidney cortex. J. Am. Chem. Soc. 1957, 79, p. 4813-4814.

25. Miles, A.T., Hawksworth, G.M., Beattie, J.H. et al. Induction, regulation, degradation, and biological significance of mammalian metallothioneins. Crit. Rev. Biochem. Mol. Biol. 2000, 35, p. 35-70.

26. Masters, B.A., Quaife, C.J., Erickson, J.C. et al. Metallothionein-Iii is expressed in neurons that sequester zinc in synaptic vesicles. J. Neurosci. 1994, 14, p. 5844-5857.

27. Quaife, C.J., Findley, S.D., Erickson, J.C. et al. Induction of a new metallothionein isoform (Mt-Iv) occurs during differentiation of stratified squamous epithelia. Biochemistry 1994, 33, p. 7250-7259.

28. Trayhurn, P., Duncan, J.S., Wood, A.M. et al. Metallothionein gene expression and secretion in white adipose tissue. Am. J. Physiol.-Regul. Integr. Comp. Physiol. 2000, 279, p. R2329-R2335.

29. Eckschlager, T., Adam, V., Hrabeta, J. et al. Metallothioneins and Cancer. Curr. Protein Pept. Sci. 2009, 10, p. 360-375.

30. Krizkova, S., Fabrik, I., Adam, V. et al. Metallothionein - a promising tool for cancer diagnostics. Bratisl. Med. J. 2009, 110, p. 93-97.

31. Krizkova, S., Blahova, P., Nakielna, J. et al. Comparison of metallothionein detection by using Brdicka reaction and enzyme-linked immunosorbent assay employing chicken yolk antibodies. Electroanalysis 2009, 21, p. 2575-2583.

32. Adam, V., Blastik, O., Krizkova, S. et al. Application of the Brdicka reaction in determination of metallothionein in patients with tumours. Chem. Listy, 2008, 102, p. 51-58.

33. Adam, V., Fabrik, I., Kizek, R. et al. Vertebrate metallothioneins as target molecules for analytical techniques. Trac-Trends Anal. Chem. 2010, 29, p. 409-418.

34. Blastik, O., Hubalek, J., Adam, V. et al. Electrochemical sensor for determination of metallothionein as biomarker. Proceedings of IEEE Sensors, Daegu, 2006, p. 1171-1174.

35. Fabrik, I., Adam, V., Krizkova, S. et al. Level of heat-stable thiols in patients with a malignant tumor. Klin. Onkol. 2007, 20, p. 384-389.

36. Fabrik, I., Kukacka, J., Adam, V. et al. Metallothionein and its relation to anticancer treatment by platinum complexes. Prakt. Lek. 2008, 88, p. 90-93.

37. Horakova, Z., Thova, E., Salzman, R. et al. Importace of elevation of metallothionein blood levels in patients with head and neck tumors - Part 2. Otorinolaryng. Foniatrie 2008, 57, p. 90-97.

38. Petrlova, J., Blastik, O., Prusa, R. et al. Determination of metallothionein content in patients with breast cancer, colon cancer, and malignant melanoma. Klin. Onkol. 2006, 19, p. 138-142.

39. Petrlova, J., Blastik, O., Prusa, R. et al. Using of electrochemical methods for studying of metallothionein content in the human blood serum of a patient poisoned by lead and treated by platinum. Biomed. Pap. Med. Fac. Univ. Palacky, Olomouc, Czechoslovakia. 2005, 149, p. 485-488.